Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin + low-dose cytarabine consolidation in elderly AML
ChiCTR2100046789Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of idarubicin and cytarabine in acute myeloid leukemia (AML), sponsored by Shanxi Cancer Hospital. Primary endpoint: 2-year disease-free survival. Started Jun 2021; status: recruiting.
02
Drugs
idarubicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100046789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046789.